The antibodies that can efficiently neutralize both the dengue and Zika virus has been identified by Scientists from the Institut Pasteur and the CNRS in collaboration with Imperial College London and the University of Vienna, Austria.
The description of the binding site for these antibodies on the viral envelope, identical for both viruses, could lead to the development of a universal vaccine that offers simultaneous protection against dengue and Zika virus disease.
‘The antibody binding site for the Zika virus is the same as for the dengue virus, which raises the possibility of producing a vaccine for two types of virus at once.’
The dengue virus and the Zika virus share several characteristics. They both belong to the Flavivirus
genus; they are both RNA viruses mainly transmitted by mosquitoes, and they have similar envelope proteins. Scientists from the Institut Pasteur, the CNRS and Imperial College London, who had previously identified antibodies capable of neutralizing the four types of dengue virus in an earlier study, decided to turn their attention to the Zika virus. "We wanted to see whether the antibodies isolated for dengue could be used to neutralize other flaviviruses, and Zika seemed like the best candidate," explained Félix Rey, Head of the Structural Virology Laboratory at the Institut Pasteur.
In this latest study, the scientists selected two antibodies capable of blocking the proliferation of the dengue virus. They began by isolating these antibodies in dengue patients, then presented them to the Zika virus. One of the antibodies proved to be highly efficient in neutralizing the Zika virus - even more so than for dengue - preventing it from infecting the cells it was cultured with. "We never expected to discover that the dengue virus and the Zika virus are so close that some antibodies produced against the dengue virus could also neutralize the Zika virus so potently," stressed Félix Rey.
The scientists then used crystallography to identify the antibody binding site on the Zika virus, and more specifically on the proteins in its viral envelope. Crystals containing the "antibody-envelope protein" complex were produced using the Institut Pasteur's Crystallography Platform. The scientists then used powerful X-rays produced by the synchrotron facilities in Saclay and Grenoble to create a 3D reconstruction of the precise location where the antibody binds to the envelope protein.
This revealed that the antibody binding site for the Zika virus was the same as for the dengue virus, raising the possibility of producing a vaccine that would stimulate the production of antibodies capable of binding to and neutralizing two types of the virus at once. Although the Zika virus was not previously thought to be dangerous, neurological complications including Guillain-Barré syndrome have been observed in Zika patients in Brazil and French Polynesia. This virus is also the cause of severe fetal brain development defects (microcephaly), resulting in irreversible intellectual disability. "The antibodies could be used, for example, to protect pregnant women at risk of contracting the Zika virus, because there is currently no vaccine or treatment for this disease," concluded Félix Rey.
The results were published in the journal Nature.